Nivolumab for advanced cancer with autoimmune disease
Treatments studied
Part of Blood & lymphatic, Bones, joints & muscles, Brain & nervous system, Cancer, Digestive system, Eyes & vision, Immune system & allergy, Mouth & dental, Skin clinical trials.
This trial tests whether the immunotherapy drug nivolumab can safely treat advanced cancer in people who also have an autoimmune disease like rheumatoid arthritis, lupus, or multiple sclerosis. It aims to find out if the drug may help control cancer while managing their autoimmune condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have advanced cancer that has spread or cannot be removed by surgery, or you need immunotherapy after surgery.
- You must be at least 18 years old.
- You must have an autoimmune disease such as rheumatoid arthritis, lupus, multiple sclerosis, or certain other conditions.
- Your cancer must not have been previously treated with PD-1/PD-L1 inhibitors (like nivolumab or pembrolizumab).
- You must be in reasonably good health, able to manage daily activities, and have adequate organ function.
- You must agree to use effective birth control if you or your partner could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a lower, less frequent dose of an immunotherapy drug called nivolumab for people with certain advanced cancers. The goal is to see if a reduced dose can still control cancer while causing fewer side effects.
This trial studies nivolumab, an immune therapy, for skin squamous cell cancer that can’t be cured with surgery or radiation. It aims to see how well the treatment shrinks tumors and helps people live longer or longer without cancer growth.
This study tests how well the immunotherapy medicine nivolumab works—either by itself or combined with other immune-boosting drugs—for people with advanced basal cell carcinoma that can’t be removed by surgery or has spread. It’s also looking at what to do if the cancer grows again after an earlier immunotherapy.
This trial tests whether adding the immunotherapy drug nivolumab to standard treatment works better for advanced stomach or esophageal cancer. It is for people whose cancer has already progressed after a first round of chemo plus immunotherapy.
This trial tests whether giving immunotherapy before surgery and possibly skipping some after may help people with advanced but removable melanoma. It aims to see if this approach can reduce the chance of the cancer coming back.
This trial studies whether an individualized “neoantigen” cancer vaccine given to immune cells (dendritic cells) plus nivolumab can improve outcomes in people with liver cancer and/or colorectal cancer that has spread only to the liver. It focuses on tumors that can be removed with curative surgery (with or without local ablation) and on people with good enough liver and overall health.
Hear when a new Dermatomyositis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.